| Evaluation and Characterization of the Effects of Ticagrelor on Serum and Urinary Uric Acid in Healthy Volunteers. | |
| | |
MedLine Citation:
|
PMID: 22190065 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
During its development, ticagrelor, a drug designed to prevent thrombotic events in patients with acute coronary syndromes, was found to have an association with mild hyperuricemia. To investigate this effect further, we carried out a placebo-controlled, randomized, crossover study in 24 healthy male volunteers. The volunteers received ticagrelor (90 mg b.i.d. for 5 days), and serum uric acid and urinary uric acid excretion were assessed under strictly controlled conditions. After administration of ticagrelor, serum uric acid significantly increased (day 1: 4-6%; day 5: 4-10%) relative to placebo and rapidly returned to baseline after the last dose of the drug. Urinary uric acid excretion was significantly higher on day 1 (7%) and at 24-48 h after the morning dose on day 5 (17%) relative to placebo. Uric acid clearance was significantly higher 24-48 h after the morning dose on day 5 (11%). Uric acid fractional excretion was unaffected. Serum hypoxanthine and xanthine were elevated after multiple ticagrelor doses. No uric acid-related adverse events were seen. The study showed that ticagrelor-associated hyperuricemia is modest and reversible; serum uric acid elevation may have been caused by altered tubular secretion and/or increase in production. |
| | |
Authors:
|
K Butler; R Teng |
Related Documents
:
|
11308025 - Acidic glycerol lipids of trichomonas vaginalis and tritrichomonas foetus. 639795 - Structural studies on the d-arabinose-containing lipid a from rhodospirillum tenue 2761. 3995915 - Selectivity in mobilisation of stored fatty acids by maturing cod, gadus morrhua l. 1467525 - Effects of tumor necrosis factor-alpha on peroxidation of plasma lipoprotein lipids in ... 11232205 - A historical perspective on the discovery of adenyl purines. 8123735 - Cholanic acids determined in commercial drugs by means of a new isfet device. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-21 |
Journal Detail:
|
Title: Clinical pharmacology and therapeutics Volume: - ISSN: 1532-6535 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372741 Medline TA: Clin Pharmacol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
AstraZeneca LP, Wilmington, Delaware, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the im...
Next Document: Pharmacokinetics of Antiretroviral Drug Varies With Formulation in the Target Population of Children...